Literature DB >> 32594120

Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors.

Emiel Leegwater1,2, Anne Strik3, Erik B Wilms1,2, Liesbeth B E Bosma1, David M Burger4, Thomas H Ottens5, Cees van Nieuwkoop3.   

Abstract

We report a case of a man with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details on this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; drug–drug interaction; hepatotoxicity; remdesivir

Year:  2021        PMID： 32594120      PMCID： PMC7337726          DOI： 10.1093/cid/ciaa883

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  23 in total

Review 1.  The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced.

Authors:  Antonio Vitiello; Raffaele La Porta; Vilma D'Aiuto; Francesco Ferrara
Journal:  Egypt Liver J       Date:  2021-01-27

2.  USA stockpiling of remdesivir: How should the world respond?

Authors:  Dalia Dawoud; Kalipso Chalkidou; Richard Sullivan; Francis J Ruiz; Amanda Adler
Journal:  J Comp Eff Res       Date:  2020-12-04       Impact factor: 1.744

3.  Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?

Authors:  Ömer Faruk Bahçecíoğlu; Selim Gök; Mefküre Durmuş
Journal:  Eur J Hosp Pharm       Date:  2021-01-20

4.  Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS.

Authors:  Wenjuan Hu; Lu Chang; Changqiang Ke; Yuanchao Xie; Jingshan Shen; Bo Tan; Jia Liu
Journal:  J Pharm Biomed Anal       Date:  2020-11-30       Impact factor: 3.935

Review 5.  Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver.

Authors:  Han-Yu Lei; Ying-He Ding; Kai Nie; Yin-Miao Dong; Jia-Hao Xu; Meng-Ling Yang; Meng-Qi Liu; Le Wei; M I Nasser; Lin-Yong Xu; Ping Zhu; Ming-Yi Zhao
Journal:  Biomed Pharmacother       Date:  2020-11-28       Impact factor: 7.419

6.  Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.

Authors:  Alpana Waghmare; Maheen Z Abidi; Michael Boeckh; Roy F Chemaly; Sanjeet Dadwal; Zeinab El Boghdadly; Mini Kamboj; Genovefa A Papanicolaou; Steven A Pergam; Zainab Shahid
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-28       Impact factor: 5.742

Review 7.  Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?

Authors:  Pierre-Jean Ferron; Thomas Gicquel; Bruno Mégarbane; Bruno Clément; Bernard Fromenty
Journal:  Biochimie       Date:  2020-09-03       Impact factor: 4.079

8.  Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study.

Authors:  Rajveer Singh; Anupam Gautam; Shivani Chandel; Arijit Ghosh; Dhritiman Dey; Syamal Roy; Velayutham Ravichandiran; Dipanjan Ghosh
Journal:  Molecules       Date:  2020-10-10       Impact factor: 4.411

9.  Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.

Authors:  Chia Siang Kow; Mamoon Aldeyab; Syed Shahzad Hasan
Journal:  Eur J Clin Pharmacol       Date:  2020-10-04       Impact factor: 2.953

10.  Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series.

Authors:  Chancey Carothers; Kara Birrer; Mai Vo
Journal:  Pharmacotherapy       Date:  2020-10-27       Impact factor: 6.251
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.